Parallax Volatility Advisers
OBIO icon

Parallax Volatility Advisers’s Orchestra BioMed OBIO Stock Holding History

Parallax Volatility Advisers’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,700
Closed -$181K – 3290
2021
Q2 		$181K Buy
+17,700
New +$183K ﹤0.01% 2475

Other funds holding OBIO

DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AC
Amitell Capital Singapore $109M AUM 50.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Parallax Volatility Advisers's OBIO Position: Q3 2021 in Review

Parallax Volatility Advisers sold out of Orchestra BioMed (OBIO) in Q3 2021, closing a stake of 17,700 shares — an estimated $181K sold.

Parallax Volatility Advisers first reported a position in OBIO in Q2 2021 and held it in 1 quarter. The position peaked at $181K in Q2 2021. 48 funds tracked by Wall St. Rank hold OBIO as of Q3 2021.

  • Parallax Volatility Advisers reported no remaining Orchestra BioMed position as of Q3 2021 after selling out during the quarter.
  • Parallax Volatility Advisers sold 17,700 Orchestra BioMed shares in Q3 2021, an estimated $181K.
  • Parallax Volatility Advisers first reported a position in Orchestra BioMed in Q2 2021 and held it in 1 quarter.
  • Parallax Volatility Advisers's Orchestra BioMed position peaked at $181K in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2021.

Based on Parallax Volatility Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.